Thursday, June 8, 2023
This activity is designed for rheumatologists, rheumatology nurse practitioners, rheumatology physician assistants, dermatologists, and other clinicians involved in the care of patients with psoriatic arthritis.
The goal of this activity is to educate healthcare professionals to be better able to evaluate patients for potential signs and symptoms of psoriatic arthritis to ensure timely and accurate diagnosis, describe the mechanisms of action and clinical data for new and emerging therapeutic approaches in the management of psoriatic arthritis, and develop patient- and disease-specific therapeutic approaches for patients with psoriatic arthritis. This on-demand panel discussion with four psoriatic arthritis specialists will connect healthcare professionals nationwide to up-to-date information on how to effectively screen for, diagnose, and treat this challenging disease.
Upon completion of this activity, participants should be able to:
Accreditor Disclosure of Conflicts of Interest Statement: In accordance with the disclosure policies of Rutgers Biomedical and Health Sciences (RBHS) and to conform with Joint Accreditation requirements and FDA guidelines, all individuals in a position to control the content of this educational activity are required to disclose to the activity participants the existence of any relevant relationships with entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exception of non-profit or government organizations and non-health care related companies, within the past 12 months. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
In order to ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, RBHS has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer.
Disclosure of Unlabeled Use: This educational activity contains information about commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Agents or classes that are not included in the labeling approved by the FDA for the treatment of psoriatic arthritis include risankizumab, tildrakizumab, brodalumab, bimekizumab, upadacitinib, filgotinib, tocilizumab, clazakizumab, baricitinib, deucravacitinib, mirikizumab, methotrexate, corticosteroids, nonsteroidal anti-inflammatory drugs, and RORγt inhibitors. This activity does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The opinions expressed in this educational activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, RBHS, or Spire Learning, LLC.
It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.
Spire Learning, LLC, and RBHS will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
Privacy Policy:
Rutgers Biomedical and Health Sciences
Please direct content or CE related questions or concerns to RBHS Center for Continuing and Outreach Education (CCOE) at 973-972-4267 or email [email protected]
To review RBHS’s CE privacy policy, click here.
Spire Learning, LLC, is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and Use of Your Personal Information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Spire Learning, LLC, to continuously improve the learning experience.
Spire Learning, LLC, will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
Rutgers Biomedical and Health Sciences designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Contact Rutgers Biomedical and Health Sciences at [email protected]
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME Released: 3/22/2021
Valid for credit through: 3/23/2022
processing....
The slides from this presentation are considered intellectual property and for use as a professional resource.
No content should be copied or reproduced in any manner for any reason.
| « Return to: Psoriatic Arthritis: Therapeutic Advances and Expert Perspectives on Managing Psoriatic Arthritis |
